THE APEX TIMES
UFC Anti-Doping: Jaqueline Amorim Accepts Six-Month Ineligibility After Ostarine Positive
Combat Sports Anti-Doping (CSAD) announced that UFC athlete Jaqueline Amorim accepted a six-month ban after out-of-competition tests detected ostarine, a prohibited anabolic agent, in two samples collected in Fort Lauderdale.
Combat Sports Anti-Doping (CSAD), which administers the UFC anti-doping program year-round, announced on October 16, 2026 that Jaqueline Amorim has accepted a six-month period of ineligibility under the UFC Anti-Doping Policy.
CSAD said Amorim tested positive for ostarine, a prohibited non-Specified Substance in the class of Anabolic Agents. The substance is prohibited at all times under the UFC ADP and UFC Prohibited List.
According to CSAD, ostarine was detected in out-of-competition samples collected on July 29, 2026 and August 17, 2026 in Fort Lauderdale, Florida. CSAD stated the two findings were combined into a single violation because the second sample was collected before Amorim was notified of the adverse analytical finding from the first sample.
CSAD said Amorim provided full and complete cooperation as defined by the UFC ADP. After reviewing the evidence, CSAD concluded the findings were consistent with exposure to low-level ostarine contamination rather than intentional use. CSAD pointed to factors including Amorim’s testing history, the low levels found in both samples, and her use of multiple dietary supplements that were not third-party tested and certified, as well as the documented prevalence of ostarine contamination in dietary supplements worldwide. CSAD also said there was no indication the exposure provided a significant performance advantage.
CSAD noted that it may reduce or suspend ineligibility when an athlete cooperates. After considering the totality of the evidence, CSAD imposed a six-month ban.
Amorim’s period of ineligibility began on August 17, 2026, the date she was notified of her provisional suspension connected to the July 29, 2026 sample, CSAD said. The ban is set to expire on February 17, 2027.
Why It Matters
- The ruling underscores that ostarine remains prohibited at all times under UFC anti-doping rules, including for out-of-competition testing.
- CSAD’s contamination finding affects the length of the sanction, illustrating how cooperation and the presence or absence of evidence for intent and performance advantage can influence outcomes.
- The case highlights UFC’s focus on supplement risk management, including third-party testing and certification.
- For UFC-related competition planning, the decision sets a clear window during which Amorim is ineligible to participate under the UFC ADP.
Key Facts
- CSAD announced that Jaqueline Amorim accepted a six-month period of ineligibility under the UFC Anti-Doping Policy.
- The violation stems from ostarine, a prohibited non-Specified Substance in the class of Anabolic Agents.
- Ostarine was detected in out-of-competition samples collected on July 29, 2026 and August 17, 2026 in Fort Lauderdale, Florida.
- CSAD combined the two test results into a single violation because the second collection occurred before notice of the first adverse finding.
- CSAD said it determined the low-level findings were consistent with contamination rather than intentional use, citing factors including low levels in both samples and the use of non-third-party-tested dietary supplements.
- Amorim’s ineligibility began on August 17, 2026 and will expire on February 17, 2027.